RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug.

PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with 3-AP in treating patients who have unresectable or metastaticpancreatic cancer.

Condition	Treatment or Intervention	Phase
stage II pancreatic cancer stage III pancreatic cancer stage IVA pancreatic cancer stage IVB pancreatic cancer recurrent pancreatic cancer	Drug: 3-AP  Drug: gemcitabine  Procedure: chemosensitization/potentiation  Procedure: chemotherapy  Procedure: enzyme inhibitor therapy	Phase II

OBJECTIVES:

• Determine the objective response rate (partial and complete response) in patients with unresectable or metastatic pancreatic cancer treated with 3-AP and gemcitabine.
• Determine the progression-free interval and survival of patients treated with this regimen.
• Determine the safety and feasibility of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive 3-AP IV over 4 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 22-40 patients will be accrued for this study.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed pancreatic cancer
• Unresectable or metastatic disease
• Measurable disease
• Outside prior radiation ports OR within prior radiation port if evidence of disease progression after radiotherapy
• No CNS metastases

PATIENT CHARACTERISTICS: Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• More than 3 months

Hematopoietic

• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 9 g/dL (transfusion allowed)

Hepatic

• Bilirubin no greater than 2.0 mg/dL
• AST and ALT less than 3 times upper limit of normal (ULN) (5 times ULN in the presence of liver metastases)
• Chronic viral hepatitis allowed

Renal

• Creatinine no greater than 2.0 mg/dL

Cardiovascular

• No myocardial infarction within the past 3 months
• No uncontrolled congestive heart failure
• No uncontrolled coronary artery disease
• No uncontrolled arrhythmias

Pulmonary

• No dyspnea at rest
• No dependence on supplemental oxygen

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No other malignancy except any of the following:
• Carcinoma in situ of the cervix treated with cone biopsy or resection
• Nonmetastatic basal cell or squamous cell skin cancer
• Any stage I malignancy curatively resected more than 5 years ago
• No active infection
• No other concurrent life threatening illness

PRIOR CONCURRENT THERAPY: Biologic therapy

• Prior vaccines, antibodies, cytokines, or small molecule cell signaling inhibitors allowed

Chemotherapy

• No prior cytotoxic chemotherapy for unresectable or metastatic pancreatic cancer

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

Surgery

• More than 3 weeks since prior surgery and recovered

Other

• More than 3 weeks since prior noncytotoxic treatment regimens and objective evidence of progressive disease

Illinois
      University of Chicago Cancer Research Center, Chicago,  Illinois,  60637-1470,  United States
Indiana
      Indiana Oncology Hematology Consultants, Indianapolis,  Indiana,  46202,  United States
Minnesota
      University of Minnesota Cancer Center, Minneapolis,  Minnesota,  55455,  United States
Tennessee
      Sarah Cannon Cancer Center at Centennial Medical Center, Nashville,  Tennessee,  37203,  United States
Belgium
      Universitair Ziekenhuis Gent, Ghent,  B-9000,  Belgium
Netherlands
      Maasland Hospital, Sittard,  6131 BK,  Netherlands
United Kingdom, England
      Christie Hospital N.H.S. Trust, Manchester,  England,  M20 4BX,  United Kingdom
      Royal Marsden Hospital - Sutton, Sutton,  England,  SM2 5PT,  United Kingdom

Study chairs or principal investigators

Mario Sznol, MD,  Study Chair,  Vion Pharmaceuticals   

Study ID Numbers:  CDR0000306461; VION-CLI-031
Record last reviewed:  August 2004
Record first received:  July 8, 2003
ClinicalTrials.gov Identifier:  NCT00064051
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-22